Venäläinen Jarkko I, Garcia-Horsman J Arturo, Forsberg Markus M, Jalkanen Aaro, Wallén Erik A A, Jarho Elina M, Christiaans Johannes A M, Gynther Jukka, Männistö Pekka T
Department of Pharmacology and Toxicology, University of Kuopio, P.O. Box 1627, Kuopio FI-70211, Finland.
Biochem Pharmacol. 2006 Feb 28;71(5):683-92. doi: 10.1016/j.bcp.2005.11.029. Epub 2006 Jan 6.
Prolyl oligopeptidase (POP) is a serine protease that specifically hydrolyses small peptides at the carboxyl end of the proline residue. POP has gained pharmaceutical interest, since its inhibitors have been shown to have antiamnesic properties in rat. We examined the effect of the 2(S)-substituents CN and COCH(2)OH at the P1 site of the parent inhibitors isophthalic acid 2(S)-(cyclopentanecarbonyl)pyrrolidine-l-prolyl-pyrrolidine amide and 4-phenylbutanoyl-l-prolyl-pyrrolidine and bulky 5-t-butyl group at the P2 site l-prolyl residue of the parent inhibitor 4-phenylbutanoyl-l-prolyl-pyrrolidine on the binding kinetics to the enzyme. In addition, we studied the duration of POP inhibition in the rat tissues in vivo after i.p. administration. CN and COCH(2)OH substituents at the P1 site pyrrolidine group were found to greatly increase the affinity of the inhibitor and the enzyme-inhibitor complex half-life. In addition, 5-t-butyl group at the P2 site l-prolyl residue increased the dissociation half-life of the enzyme-inhibitor complex, without much affecting the inhibitory potency. The duration of the inhibition in the rat tissues followed the inhibition kinetic properties in that the compounds with fast dissociation produced shorter inhibition in the rat tissues than the compounds with slow dissociation. The duration of POP inhibition of compounds was evidently not governed by their serum clearance. The fact that the in vivo pharmacodynamic behaviour of POP inhibitors can be predicted by their in vitro-properties may be of importance when designing therapeutically useful POP inhibitors.
脯氨酰寡肽酶(POP)是一种丝氨酸蛋白酶,可特异性水解脯氨酸残基羧基末端的小肽。由于其抑制剂已被证明在大鼠中具有抗遗忘特性,因此POP已引起制药领域的关注。我们研究了母体抑制剂间苯二甲酸2(S)-(环戊烷羰基)吡咯烷-1-脯氨酰-吡咯烷酰胺和4-苯基丁酰基-1-脯氨酰-吡咯烷在P1位点的2(S)-取代基CN和COCH(2)OH以及母体抑制剂4-苯基丁酰基-1-脯氨酰-吡咯烷在P2位点脯氨酰残基上的庞大5-叔丁基对与该酶结合动力学的影响。此外,我们研究了腹腔注射后在大鼠组织中体内POP抑制的持续时间。发现P1位点吡咯烷基上的CN和COCH(2)OH取代基大大增加了抑制剂的亲和力以及酶-抑制剂复合物的半衰期。此外,P2位点脯氨酰残基上的5-叔丁基增加了酶-抑制剂复合物的解离半衰期,而对抑制效力影响不大。大鼠组织中的抑制持续时间遵循抑制动力学特性,即解离快的化合物在大鼠组织中的抑制作用比解离慢的化合物短。POP抑制剂的抑制持续时间显然不受其血清清除率的控制。在设计具有治疗用途的POP抑制剂时,POP抑制剂的体内药效学行为可通过其体外特性进行预测这一事实可能很重要。